Table 1.
Comparative analysis of Parkinson disease subjects receiving intrajejunal therapy and oral therapy group.
| Intrajejunal therapy (n = 24) | Oral therapy (n = 37) | P value | |
| Age (years), mean (SD) | 70.12 (7.66) | 70.59 (9.11) | .835 |
| Gender (female), n (%) | 11 (45.83) | 8 (21.62) | .046 |
| Place of residence (rural), n (%) | 3 (12.5) | 2 (5.41) | .373 |
| Duration of PD (years), median (IQR) | 15 (13.75–20.25) | 9 (6–13) | <.001 |
| Duration from initiation of therapy (years), median (IQR) | 5 (3.75–7) | 4 (3–6) | .461 |
| Hoehn şi Yahr stages la baseline | |||
| 3 | 2 (9.09) | 29 (78.38) | <.001 |
| 4 | 20 (90.91) | 8 (21.62) | |
| UPDRS II at baseline, median (IQR) | 37 (33–39) | 17 (13–24) | < .001 |
| UPDRS II at 1 year, median (IQR) | 27 (21–31.5) | 24 (19–31) | .27 |
| UDPRS II Diference at 1 year -baseline, median (IQR) | 10 (6–12.5) | -7 (-8–-5) | <.001 |
| UPDRS III at baseline, median (IQR) | 41.5 (38–45) | 24 (18–27) | <.001 |
| UPDRS III at 1 year, median (IQR) | 30 (28.5–35.5) | 30 (26–34) | .307 |
| UDPRS III Diference at 1 year-baseline, median (IQR) | 11 (8.5–13) | −7 (−10–5) | <.001 |
| Dyskinesia at baseline, n (%) | 17 (70.83) | 5 (13.51) | <.001 |
| Dyskinesia at 1 year, n (%) | 8 (33.33) | 6 (16.22) | .12 |
| Dyskinesia evolution in 1 year, n (%) | |||
| dissapearing: | 10 (41.67) | 0 (0) | <.001 |
| absent: | 6 (25) | 31 (83.78) | |
| persistent: | 7 (29.17) | 5 (13.51) | |
| newly occured: | 1 (4.17) | 1 (2.7) | |
| Dyskinesia evolution at 12 months (improvement vs. same or worsening), n (%) | 10 (41.67) | 0 (0) | <.001 |
| Wearing off/On-Off at baseline, n (%) | 24 (100) | 10 (27.03) | <.001 |
| Wearing off/On-Off at 1 year, n (%) | 17 (70.83) | 14 (37.84) | .012 |
| Wearing off/On-Off evolution in 1 year, n (%) | |||
| dissapearing: | 7 (29.17) | 1 (2.7) | <.001 |
| absent: | 0 (0) | 22 (59.46) | |
| persistent: | 17 (70.83) | 9 (24.32) | |
| newly occured: | 0 (0) | 5 (13.51) | |
| Wearing off/On-Off evolution at 12 months (improvement vs. same or worsening), n (%) | 7 (29.17) | 1 (2.7) | .005 |
| Deep brain stimulation, n (%) | 1 (4.17) | 0 (0) | .393 |
| Decease, n (%) | 6 (25) | 3 (8.11) | .136 |
| Mixed anxiety–depressive disorder, n (%) | 13 (54.17) | 8 (21.62) | .009 |
| Mild cognitive impairment, n (%) | 10 (41.67) | 14 (37.84) | .765 |
| Parkinson Dementia, n (%) | 4 (16.67) | 4 (10.81) | .7 |
| Drug-induced psychosis, n (%) | 5 (20.83) | 0 (0) | .007 |
| Hypertension, n (%) | 6 (25) | 21 (56.76) | .015 |
| Permanent atrial fibrilation, n (%) | 1 (4.17) | 4 (10.81) | .64 |
| Ischaemic Stroke / cerebral lacunarism, n (%) | 5 (20.83) | 16 (44.44) | .06 |
| Diabetes type II, n (%) | 1 (4.17) | 8 (21.62) | .076 |
| Polyneuropathy, n (%) | 16 (66.67) | 22 (61.11) | .662 |
| Dyslipidemia, n (%) | 3 (12.5) | 7 (18.92) | .726 |
| Iron deficiency anemia, n (%) | 5 (20.83) | 1 (2.78) | .033 |
| Folate-deficiency anemia, n (%) | 5 (20.83) | 6 (16.67) | .741 |
| Vitamin B12 deficiency, n (%) | 2 (8.33) | 4 (11.11) | 1 |